Alternative splicing of pre-mRNA in cancer: Focus on G protein-coupled peptide hormone receptors

Meike Körner, Laurence J Miller

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Through alternative splicing, multiple different transcripts can be generated from a single gene. Alternative splicing represents an important molecular mechanism of gene regulation in physiological processes such as developmental programming as well as in disease. In cancer, splicing is significantly altered. Tumors express a different collection of alternative spliceoforms than normal tissues. Many tumor-associated splice variants arise from genes with an established role in carcinogenesis or tumor progression, and their functions can be oncogenic. This raises the possibility that products of alternative splicing play a pathogenic role in cancer. Moreover, cancer-associated spliceoforms represent potential diagnostic biomarkers and therapeutic targets. G protein-coupled peptide hormone receptors provide a good illustration of alternative splicing in cancer. The wild-type forms of these receptors have long been known to be expressed in cancer and to modulate tumor cell functions. They are also recognized as attractive clinical targets. Recently, splice variants of these receptors have been increasingly identified in various types of cancer. In particular, alternative cholecystokinin type 2, secretin, and growth hormone-releasing hormone receptor spliceoforms are expressed in tumors. Peptide hormone receptor splice variants can fundamentally differ from their wild-type receptor counterparts in pharmacological and functional characteristics , in their distribution in normal and malignant tissues , and in their potential use for clinical applications.

Original languageEnglish (US)
Pages (from-to)461-472
Number of pages12
JournalAmerican Journal of Pathology
Volume175
Issue number2
DOIs
StatePublished - Aug 2009

Fingerprint

Peptide Receptors
RNA Precursors
Alternative Splicing
GTP-Binding Proteins
Neoplasms
Physiological Phenomena
Genes
Secretin
Normal Distribution
Cholecystokinin
Carcinogenesis
Biomarkers
Pharmacology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Alternative splicing of pre-mRNA in cancer : Focus on G protein-coupled peptide hormone receptors. / Körner, Meike; Miller, Laurence J.

In: American Journal of Pathology, Vol. 175, No. 2, 08.2009, p. 461-472.

Research output: Contribution to journalArticle

@article{b1a31958b72d4b08b48625c4e36841de,
title = "Alternative splicing of pre-mRNA in cancer: Focus on G protein-coupled peptide hormone receptors",
abstract = "Through alternative splicing, multiple different transcripts can be generated from a single gene. Alternative splicing represents an important molecular mechanism of gene regulation in physiological processes such as developmental programming as well as in disease. In cancer, splicing is significantly altered. Tumors express a different collection of alternative spliceoforms than normal tissues. Many tumor-associated splice variants arise from genes with an established role in carcinogenesis or tumor progression, and their functions can be oncogenic. This raises the possibility that products of alternative splicing play a pathogenic role in cancer. Moreover, cancer-associated spliceoforms represent potential diagnostic biomarkers and therapeutic targets. G protein-coupled peptide hormone receptors provide a good illustration of alternative splicing in cancer. The wild-type forms of these receptors have long been known to be expressed in cancer and to modulate tumor cell functions. They are also recognized as attractive clinical targets. Recently, splice variants of these receptors have been increasingly identified in various types of cancer. In particular, alternative cholecystokinin type 2, secretin, and growth hormone-releasing hormone receptor spliceoforms are expressed in tumors. Peptide hormone receptor splice variants can fundamentally differ from their wild-type receptor counterparts in pharmacological and functional characteristics , in their distribution in normal and malignant tissues , and in their potential use for clinical applications.",
author = "Meike K{\"o}rner and Miller, {Laurence J}",
year = "2009",
month = "8",
doi = "10.2353/ajpath.2009.081135",
language = "English (US)",
volume = "175",
pages = "461--472",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Alternative splicing of pre-mRNA in cancer

T2 - Focus on G protein-coupled peptide hormone receptors

AU - Körner, Meike

AU - Miller, Laurence J

PY - 2009/8

Y1 - 2009/8

N2 - Through alternative splicing, multiple different transcripts can be generated from a single gene. Alternative splicing represents an important molecular mechanism of gene regulation in physiological processes such as developmental programming as well as in disease. In cancer, splicing is significantly altered. Tumors express a different collection of alternative spliceoforms than normal tissues. Many tumor-associated splice variants arise from genes with an established role in carcinogenesis or tumor progression, and their functions can be oncogenic. This raises the possibility that products of alternative splicing play a pathogenic role in cancer. Moreover, cancer-associated spliceoforms represent potential diagnostic biomarkers and therapeutic targets. G protein-coupled peptide hormone receptors provide a good illustration of alternative splicing in cancer. The wild-type forms of these receptors have long been known to be expressed in cancer and to modulate tumor cell functions. They are also recognized as attractive clinical targets. Recently, splice variants of these receptors have been increasingly identified in various types of cancer. In particular, alternative cholecystokinin type 2, secretin, and growth hormone-releasing hormone receptor spliceoforms are expressed in tumors. Peptide hormone receptor splice variants can fundamentally differ from their wild-type receptor counterparts in pharmacological and functional characteristics , in their distribution in normal and malignant tissues , and in their potential use for clinical applications.

AB - Through alternative splicing, multiple different transcripts can be generated from a single gene. Alternative splicing represents an important molecular mechanism of gene regulation in physiological processes such as developmental programming as well as in disease. In cancer, splicing is significantly altered. Tumors express a different collection of alternative spliceoforms than normal tissues. Many tumor-associated splice variants arise from genes with an established role in carcinogenesis or tumor progression, and their functions can be oncogenic. This raises the possibility that products of alternative splicing play a pathogenic role in cancer. Moreover, cancer-associated spliceoforms represent potential diagnostic biomarkers and therapeutic targets. G protein-coupled peptide hormone receptors provide a good illustration of alternative splicing in cancer. The wild-type forms of these receptors have long been known to be expressed in cancer and to modulate tumor cell functions. They are also recognized as attractive clinical targets. Recently, splice variants of these receptors have been increasingly identified in various types of cancer. In particular, alternative cholecystokinin type 2, secretin, and growth hormone-releasing hormone receptor spliceoforms are expressed in tumors. Peptide hormone receptor splice variants can fundamentally differ from their wild-type receptor counterparts in pharmacological and functional characteristics , in their distribution in normal and malignant tissues , and in their potential use for clinical applications.

UR - http://www.scopus.com/inward/record.url?scp=68449085340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449085340&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2009.081135

DO - 10.2353/ajpath.2009.081135

M3 - Article

C2 - 19574427

AN - SCOPUS:68449085340

VL - 175

SP - 461

EP - 472

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -